Journal of psychopharmacology (Oxford, England)
A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.
Gerard J Marek, Soma Makai-Bölöni, Daniel Umbricht, Edward P Christian, Jason Winters, Dino Dvorak, Shane Raines, Zoë A Hughes, Eric W Austin, Adam K Klein, William Leong, Fas J Krol, Anne J van der Graaf, Maria J Juachon, Marije E Otto
Published: 202510.1177/02698811251378512
Abstract
BACKGROUND: The treatment of major depressive disorder (MDD) with available antidepressant drugs is characterized by considerable ineffectiveness. Classical psychedelics such as psilocybin and N,N-dimethyltryptamine (DMT), which act primarily as 5-hy…
Preview only. Read the full abstract at the source